ES2367576T3 - Nuevos compuestos como moduladores de receptores opioides. - Google Patents

Nuevos compuestos como moduladores de receptores opioides. Download PDF

Info

Publication number
ES2367576T3
ES2367576T3 ES05728171T ES05728171T ES2367576T3 ES 2367576 T3 ES2367576 T3 ES 2367576T3 ES 05728171 T ES05728171 T ES 05728171T ES 05728171 T ES05728171 T ES 05728171T ES 2367576 T3 ES2367576 T3 ES 2367576T3
Authority
ES
Spain
Prior art keywords
alkyl
aryl
optionally substituted
alkoxy
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05728171T
Other languages
English (en)
Inventor
Henry J. Breslin
Chaozhong Cai
Wei He
Robert W. Kavash
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34962827&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2367576(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of ES2367576T3 publication Critical patent/ES2367576T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Amplitude Modulation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Eye Examination Apparatus (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Amplifiers (AREA)
  • Steroid Compounds (AREA)

Abstract

Un compuesto de Formula (I) **Fórmula** en la que: R1 se selecciona entre el grupo que consiste en hidrogeno, alquilo C1-6, cicloalquilo, heterociclilo, arilalquilo (C1- 6) y heteroarilalquilo (C1-6); en la que cuando R1 es fenilalquilo (C1-6), fenilo esta opcionalmente condensado a un heterociclilo o cicloalquilo; en la que cuando R1 es alquilo C1-2, dicho alquilo C1-2 esta opcionalmente sustituido con uno a dos sustituyentes seleccionados independientemente entre el grupo que consiste en alcoxi C1-6, arilo, cicloalquilo, heterociclilo, hidroxi, ciano, amino, alquilamino C1-6, (alquil C1-6)2amino, trifluorometilo y carboxi; y adicionalmente, en la que cuando R1 es alquilo C3-6, dicho alquilo C3-6 esta opcionalmente sustituido con uno a tres sustituyentes seleccionados independientemente entre el grupo que consiste en alcoxi C1-6, arilo, cicloalquilo, heterociclilo, hidroxi, ciano, amino, alquilamino C1-6, (alquil C1-6)2amino, trifluorometilo y carboxi; en la que el cicloalquilo y el heterociclilo de alquilo C1-2 y alquilo C3-6 estan opcionalmente sustituidos con uno a dos sustituyentes seleccionados independientemente entre el grupo que consiste en alquilo C1-6, hidroxialquilo (C1-6), alcoxi C1-6, hidroxi, ciano, amino, alquilamino C1-6, (alquil C1-6)2amino, trifluorometilo, carboxi, arilalcoxicarbonilo (C1-6), alcoxicarbonilo C1-6, aminocarbonilo, alquilaminocarbonilo C1-6, (alquil C1- 6)2aminocarbonilo y aminosulfonilo; ademas, en la que el cicloalquilo y el heterociclilo de R1 estan opcionalmente sustituidos con uno a dos sustituyentes seleccionados independientemente entre el grupo que consiste en alquilo C1-6, hidroxialquilo (C1-6), alcoxi C1-6, hidroxi, ciano, amino, alquilamino C1-6, (alquil C1-6)2amino, trifluorometilo, carboxi, arilalcoxicarbonilo (C1-6), alcoxicarbonilo C1-6, aminocarbonilo, alquilaminocarbonilo C1-6, (alquil C1-6)2aminocarbonilo y aminosulfonilo; ademas, en la que la porcion de arilo y heteroarilo de los sustituyentes R1 arilalquilo (C1-6) y heteroarilalquilo (C1- 6), esta opcionalmente sustituida con uno a tres sustituyentes R11 seleccionados independientemente entre el grupo que consiste en alquilo C1-6; hidroxialquilo (C1-6); alcoxi C1-6; aril C6-10-alquilo (C1-6); aril C6-10-alcoxi (C1-6); arilo C6-10; heteroarilo opcionalmente sustituido con uno a dos sustituyentes seleccionados independientemente entre el grupo que consiste en alquilo C1-4, alcoxi C1-4 y carboxi; cicloalquilo; heterociclilo; ariloxi C6-10; heteroariloxi; cicloalquiloxi; heterocicliloxi; amino; alquilamino C1-6; (alquil C1-6)2amino; cicloalquilaminocarbonilo C3-6; hidroxialquilaminocarbonilo (C1-6); arilaminocarbonilo C6-10 en la que arilo C6-10 esta opcionalmente sustituido con carboxi o alcoxicarbonilo C1-4; heterociclilcarbonilo; carboxi; alcoxicarbonilo C1-6; alcoxicarboniloxi C1-6; alquilcarbonilo C1-6; alquilcarbonilamino C1-6; aminocarbonilo; alquilaminocarbonilo C1-6; (alquil C1- 6)2aminocarbonilo; ciano; halogeno; trifluorometilo; trifluorometoxi; e hidroxi; con la condicion de que no mas de un sustituyente R11 se seleccione entre el grupo que consiste en aril C6-10- alquilo (C1-6); aril C6-10-alcoxi (C1-6); arilo C6-10; heteroarilo opcionalmente sustituido con uno a dos sustituyentes seleccionados independientemente entre el grupo que consiste en alquilo C1-4, alcoxi C1-4 y carboxi; cicloalquilo; heterociclilo; ariloxi C6-10; heteroariloxi; cicloalquiloxi; arilaminocarbonilo C6-10 en la que arilo C6-10 esta opcionalmente sustituido con carboxi o alcoxicarbonilo C1-4; heterociclilcarbonilo y heterocicliloxi; R2 es hidrogeno, alquilo C1-8, hidroxialquilo (C1-8), aril C6-10-alcoxi (C1-6)-alquilo (C1-6) o aril C6-10-alquilo (C1-8); en la que el grupo arilo C6-10 en los sustituyentes que contienen arilo C6-10 de R2 estan opcionalmente sustituidos con uno a dos sustituyentes seleccionados independientemente entre el grupo que consiste en alquilo C1-6, alcoxi C1-6, hidroxi, amino, alquilamino C1-6, (alquil C1-6)2amino, aminocarbonilo, alquilaminocarbonilo C1-6, (alquil C1-6)2aminocarbonilo, ciano, fluor, cloro, bromo, trifluorometilo y trifluorometoxi; y, en la que los sustituyentes alquilo C1-6 y alcoxi C1-6 de arilo estan opcionalmente sustituidos con hidroxi, amino, alquilamino C1-6, (alquil C1- 6)2amino o arilo; A es a-1, opcionalmente sustituido con R3 y R5; en la que A-B es N-C; R3 es de uno a dos sustituyentes seleccionados independientemente entre el grupo que consiste en alquilo C1-6, arilo, arilalquilo (C1-6), arilalquenilo (C2-6), arilalquinilo (C2-6), heteroarilo, heteroarilalquilo (C1-6), heteroarilalquenilo (C2-6), heteroarilalquinilo (C2-6), amino, alquilamino C1-6, (alquil C1-6)2amino, arilamino, heteroarilamino, ariloxi, heteroariloxi, trifluorometilo y halogeno; en la que el arilo, heteroarilo y el arilo y heteroarilo de arilalquilo (C1-6), arilalquenilo (C2-6), arilalquinilo (C2-6), heteroarilalquilo (C1-6), heteroarilalquenilo (C2-6), heteroarilalquinilo (C2-6), arilamino, heteroarilamino, ariloxi y heteroariloxi, estan opcionalmente sustituidos con uno a cinco sustituyentes fluor o uno a tres sustituyentes seleccionados independientemente entre el grupo que consiste en alquilo C1-6, hidroxialquilo (C1-6), alcoxi C1-6, aril C6-10-alquilo (C1-6), aril C6-10-alcoxi (C1-6), arilo C6-10, ariloxi C6-10, heteroarilalquilo (C1-6), heteroarilalcoxi (C1- 6), heteroarilo, heteroariloxi, arilamino C6-10, heteroarilamino, amino, alquilamino C1-6, (alquil C1-6)2amino, carboxialquilamino (C1-6), carboxi, alquilcarbonilo C1-6, alcoxicarbonilo C1-6, alquilcarbonilamino C1-6, aminocarbonilo, alquilaminocarbonilo C1-6, (alquil C1-6)2aminocarbonilo, carboxialquilaminocarbonilo (C1-6), ciano, halogeno, trifluorometilo, trifluorometoxi, hidroxi, alquilsulfonilo C1-6 y alquilsulfonilamino C1-6; con la condicion de que no mas de uno de dichos sustituyentes en la porcion arilo o heteroarilo de R3 se seleccione entre el grupo que consiste en aril C6-10-alquilo (C1-6), aril C6-10-alcoxi (C1-6), arilo C6-10, ariloxi C6-10, heteroarilalquilo (C1-6), heteroarilalcoxi (C1-6), heteroarilo, heteroariloxi, arilamino C6-10, heteroarilamino; y en la que alquilo C1-6 y alquilo C1-6 de arilalquilo (C1-6) y heteroarilalquilo (C1-6) estan opcionalmente sustituidos con un sustituyente seleccionado entre el grupo que consiste en hidroxi, carboxi, alcoxicarbonilo C1-4, amino, alquilamino C1-6, (alquil C1-6)2amino, aminocarbonilo, alquilaminocarbonilo (C1-4), dialquilaminocarbonilo (C1-4), arilo, heteroarilo, arilamino, heteroarilamino, ariloxi, heteroariloxi, arilalcoxi (C1-4) y heteroarilalcoxi (C1-4); R4 es arilo C6-10 o un heteroarilo seleccionado entre el grupo que consiste en furilo, tienilo, pirrolilo, oxazolilo, tiazolilo, imidazolilo, pirazolilo, piridinilo, pirimidinilo, pirazinilo, indolilo, isoindolilo, indolinilo, benzofurilo, benzotienilo, bencimidazolilo, benztiazolilo, benzoxazolilo, quinolizinilo, quinolinilo, isoquinolinilo y quinazolinilo; en la que R4 esta opcionalmente sustituido con uno a tres sustituyentes R41 seleccionados independientemente entre el grupo que consiste en alquilo (C1-6) opcionalmente sustituido con amino, alquilamino C1-6 o (alquil C1- 6)2amino; alcoxi (C1-6); fenilalcoxi (C1-6); fenilalquilcarboniloxi (C1-6) en la que alquilo C1-6 esta opcionalmente sustituido con amino; un heteroarilalquilcarboniloxi (C1-6) no condensado de 5 miembros; un heteroarilo no condensado de 5 miembros; hidroxi; halogeno; aminosulfonilo; formilamino; aminocarbonilo; alquilaminocarbonilo C1-6 en la que alquilo (C1-6) esta opcionalmente sustituido con amino, alquilamino C1-6 o (alquil C1-6)2amino; (alquil C1-6)2aminocarbonilo en la que cada alquilo (C1-6) esta opcionalmente sustituido con amino, alquilamino C1-6 o (alquil C1-6)2amino; heterociclilcarbonilo en la que heterociclilo es un anillo que contiene nitrogeno de 5-7 miembros y dicho heterociclilo esta unido al carbono carbonilo a traves de un atomo de nitrogeno; carboxi; o ciano; y en la que la porcion fenilo de fenilalquilcarboniloxi (C1-6) esta opcionalmente sustituida con alquilo (C1-6)-alcoxi (C1-6), halogeno, ciano, amino o hidroxi; con la condicion de que no mas de un R41 sea alquilo C1-6 sustituido con alquilamino C1-6 o (alquil C1-6)2amino; aminosulfonilo; formilamino; aminocarbonilo; alquilaminocarbonilo C1-6; (alquil C1-6)2aminocarbonilo; heterociclilcarbonilo; hidroxi; carboxi; o un sustituyente que contiene fenilo o heteroarilo; R5 es un sustituyente en un atomo de nitrogeno del anillo A seleccionado entre el grupo que consiste en hidrogeno y alquilo C1-4; R6 es hidrogeno o alquilo C1-6; R7 es hidrogeno o alquilo C1-6; Ra Rb y se seleccionan independientemente entre el grupo que consiste en hidrogeno, alquilo C1-6 y alcoxicarbonilo C1-6; como alternativa, cuando cada uno de Ra y Rb es distinto de hidrogeno, Ra y Rb se toman opcionalmente junto con el atomo de nitrogeno al que ambos estan unidos para formar un anillo monociclico de cinco a ocho miembros; L es O; y enantiomeros, diastereomeros, racematos y sales farmaceuticamente aceptables del mismo.
ES05728171T 2004-03-15 2005-03-14 Nuevos compuestos como moduladores de receptores opioides. Expired - Lifetime ES2367576T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55334204P 2004-03-15 2004-03-15
US553342P 2004-03-15

Publications (1)

Publication Number Publication Date
ES2367576T3 true ES2367576T3 (es) 2011-11-04

Family

ID=34962827

Family Applications (5)

Application Number Title Priority Date Filing Date
ES12194058.9T Expired - Lifetime ES2533176T3 (es) 2004-03-15 2005-03-14 Proceso para preparar intermedios de compuestos útiles como moduladores de receptores opioides
ES16178050T Expired - Lifetime ES2705077T3 (es) 2004-03-15 2005-03-14 Moduladores de receptores opioides
ES10182349T Expired - Lifetime ES2428008T3 (es) 2004-03-15 2005-03-14 Moduladores de receptores opioides
ES05728171T Expired - Lifetime ES2367576T3 (es) 2004-03-15 2005-03-14 Nuevos compuestos como moduladores de receptores opioides.
ES13173454.3T Expired - Lifetime ES2596434T3 (es) 2004-03-15 2005-03-14 Moduladores de receptores opioides

Family Applications Before (3)

Application Number Title Priority Date Filing Date
ES12194058.9T Expired - Lifetime ES2533176T3 (es) 2004-03-15 2005-03-14 Proceso para preparar intermedios de compuestos útiles como moduladores de receptores opioides
ES16178050T Expired - Lifetime ES2705077T3 (es) 2004-03-15 2005-03-14 Moduladores de receptores opioides
ES10182349T Expired - Lifetime ES2428008T3 (es) 2004-03-15 2005-03-14 Moduladores de receptores opioides

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES13173454.3T Expired - Lifetime ES2596434T3 (es) 2004-03-15 2005-03-14 Moduladores de receptores opioides

Country Status (35)

Country Link
US (8) US7741356B2 (es)
EP (5) EP2573068B9 (es)
JP (1) JP4778954B2 (es)
KR (1) KR101166342B1 (es)
CN (2) CN1950342B (es)
AR (2) AR048269A1 (es)
AT (1) ATE516274T1 (es)
AU (1) AU2005224091B2 (es)
BR (1) BRPI0508820B8 (es)
CA (1) CA2560047C (es)
CR (1) CR8655A (es)
CY (3) CY1111927T1 (es)
DK (5) DK2653465T3 (es)
EC (1) ECSP066856A (es)
ES (5) ES2533176T3 (es)
HR (4) HRP20110694T1 (es)
HU (2) HUE029852T2 (es)
IL (3) IL178040A (es)
LT (2) LT2653465T (es)
LU (1) LUC00007I2 (es)
ME (3) ME02221B (es)
MX (1) MXPA06010642A (es)
MY (1) MY146972A (es)
NL (1) NL300865I2 (es)
NO (3) NO338203B1 (es)
NZ (1) NZ549842A (es)
PH (1) PH12012501640B1 (es)
PL (4) PL2653465T3 (es)
PT (4) PT2298744E (es)
RS (4) RS52933B (es)
SI (4) SI2573068T1 (es)
TW (1) TWI361069B (es)
UA (1) UA86053C2 (es)
WO (1) WO2005090315A1 (es)
ZA (1) ZA200608587B (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
AU2005224091B2 (en) 2004-03-15 2012-02-02 Janssen Pharmaceutica, N.V. Novel compounds as opioid receptor modulators
MXPA06013270A (es) 2004-05-14 2007-04-23 Johnson & Johnson Compuestos de opioide carboxamido.
EP1838348B1 (en) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanized amyloid beta antibodies for use in improving cognition
AU2006223482A1 (en) * 2005-03-14 2006-09-21 Janssen Pharmaceutica, N.V. Process for the preparation of opioid modulators
NZ568595A (en) 2005-12-14 2010-04-30 Bristol Myers Squibb Co Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor Xla inhibitors
UA96283C2 (uk) * 2005-12-23 2011-10-25 Зіланд Фарма А/С Модифіковані міметики лізину
RU2494108C2 (ru) 2006-04-07 2013-09-27 Аерпио Терапетикс, Инк. Антитела, которые связывают человеческий белок бета-тирозин фосфатазу (нртрвета), и их использование
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
EP2074087A2 (en) 2006-12-21 2009-07-01 Wyeth Synthesis of pyrrolidine compounds
AU2008275270C1 (en) * 2007-07-09 2014-04-17 Allergan Holdings Unlimited Company Novel crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
DK2182983T3 (da) 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
TWI468375B (zh) * 2008-10-27 2015-01-11 Janssen Pharmaceutica Nv 製備經保護之ｌ－丙胺酸衍生物之方法
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
JP5198220B2 (ja) * 2008-11-13 2013-05-15 東ソ−・エフテック株式会社 アミノ酸誘導体の製造方法
ES2726946T3 (es) 2009-07-06 2019-10-10 Aerpio Therapeutics Inc Derivados de benzosulfonamida, composiciones de los mismos y su uso en la prevención de la metástasis de las células cancerosas
EP2524912A1 (en) 2011-05-16 2012-11-21 Bionomics Limited Amine derivatives
CN103781763B (zh) 2011-05-16 2017-03-22 生态学有限公司 作为钾通道阻断剂的胺衍生物
WO2013056240A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
KR102028793B1 (ko) 2013-03-14 2019-10-07 에피자임, 인코포레이티드 아르기닌 메틸기 전이효소 억제제 및 이의 용도
US9675587B2 (en) * 2013-03-14 2017-06-13 Allergan Holdings Unlimited Company Opioid receptor modulator dosage formulations
EP2970135B1 (en) 2013-03-14 2018-07-18 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2014153172A1 (en) * 2013-03-14 2014-09-25 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
EP3116503A4 (en) 2014-03-14 2017-08-23 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
IS2977B (is) 2015-02-23 2017-07-15 Actavis Group Ptc Ehf. Aðferð til framleiðslu á milliefnum sem eru nytsamleg við nýsmíði á elúxadólíni
WO2017007695A1 (en) 2015-07-09 2017-01-12 The Regents Of The University Of California Mu opioid receptor modulators
US10314819B2 (en) 2015-07-23 2019-06-11 Teva Pharmaceuticals International Gmbh Solid state forms of Eluxadoline
WO2017043626A1 (ja) * 2015-09-11 2017-03-16 株式会社カネカ 光学活性４－カルバモイル－２，６－ジメチルフェニルアラニン誘導体の製造法
ES2894802T3 (es) 2015-09-23 2022-02-15 Aerpio Pharmaceuticals Inc Activadores de Tie-2 para su uso en el tratamiento de la presión intraocular
CN105250232B (zh) * 2015-09-29 2018-08-14 江苏汇智知识产权服务有限公司 一种伊卢多啉肠溶片及其制备方法
WO2017114446A1 (zh) * 2015-12-31 2017-07-06 苏州晶云药物科技有限公司 艾沙度林的新晶型及其制备方法
EP3272741A1 (en) 2016-07-21 2018-01-24 Euticals S.P.A. New stable solvate crystalline forms of eluxadoline
CN105777584B (zh) * 2016-03-28 2018-01-02 成都伊诺达博医药科技有限公司 丙氨酸衍生物的制备方法
CN105693554B (zh) * 2016-04-06 2017-08-08 成都伊诺达博医药科技有限公司 丙氨酸衍生物的制备方法
US20190177281A1 (en) * 2016-05-03 2019-06-13 Sromovasam THIRUMALAI RAJAN Process for the preparation of 5-[[[(2s)-2-amino-3-[4-(aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl] [(1s)-1-(4-phenyl-1h-imidazol-2-yl)ethyl]amino] methyl-2-methoxybenzoic acid and its polymorphs thereof
US20190177282A1 (en) * 2016-05-30 2019-06-13 Sun Pharmaceutical Industries Limited A process for the preparation of eluxadoline
EP3474847B1 (en) * 2016-06-23 2022-09-07 Sun Pharmaceutical Industries Limited Processes for the preparation of eluxadoline
WO2018020450A2 (en) 2016-07-28 2018-02-01 Lupin Limited Process for the preparation of eluxadoline
CZ2016548A3 (cs) 2016-09-07 2018-03-14 Zentiva, K.S. Pevné formy eluxadolinu
WO2018047131A1 (en) * 2016-09-09 2018-03-15 Sun Pharmaceutical Industries Limited Amorphous eluxadoline
WO2018055528A2 (en) * 2016-09-20 2018-03-29 Sun Pharmaceutical Industries Limited Processes for the preparation of eluxadoline
EP3573958A1 (en) 2017-01-27 2019-12-04 Quimica Sintetica, S.A. Eluxadoline crystalline forms and processes for their preparation
WO2018138272A1 (en) 2017-01-27 2018-08-02 Quimica Sintetica, S. A. Eluxadoline crystalline form and process for the preparation thereof
CN110709096B (zh) 2017-05-05 2023-10-31 泽兰德制药公司 细胞间隙连接通讯调节剂及其在糖尿病性眼病治疗中的应用
WO2019008604A1 (en) 2017-07-07 2019-01-10 Cipla Limited NEW FORMS OF MU-OPIOID RECEPTOR AGONIST
WO2019144805A1 (zh) * 2018-01-25 2019-08-01 四川科伦博泰生物医药股份有限公司 取代的苯乙胺化合物及其制备方法和用途
WO2019197274A1 (en) 2018-04-09 2019-10-17 Quimica Sintetica, S. A. Process for the preparation of opioid modulators
US20210251964A1 (en) 2018-08-20 2021-08-19 Allergan Holdings Unlimited Company Polymorphs of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
WO2020068653A1 (en) 2018-09-24 2020-04-02 Aerpio Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF
ES2867895T3 (es) * 2018-11-30 2021-10-21 Phytobiotics Futterzusatzstoffe Gmbh Sistema para el análisis de imágenes de excrementos de animales
CN111377832A (zh) * 2018-12-27 2020-07-07 江苏联昇化学有限公司 一种伊卢多啉中间体制备的新方法
EP3962482A4 (en) 2019-04-29 2023-01-11 EyePoint Pharmaceuticals, Inc. TIE 2 ACTIVATORS FACING THE SCHLEMM CHANNEL
US20230118152A1 (en) 2020-03-30 2023-04-20 Allergan Holdings Unlimited Company Forms of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
IL300110A (en) * 2020-07-28 2023-03-01 Jazz Pharmaceuticals Ireland Ltd Chiral synthesis of fused bicyclic raf inhibitors
US12115269B2 (en) 2020-09-29 2024-10-15 ABL Holding Holding LLC Techniques for directing ultraviolet energy towards a moving surface
US11850319B2 (en) 2020-09-29 2023-12-26 Abl Ip Holding Llc Techniques for directing ultraviolet energy towards a moving surface
CN114163348A (zh) * 2020-11-27 2022-03-11 成都泰蓉生物科技有限公司 一种氨酰基取代的l-苯丙氨酸的合成方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD142804A3 (de) * 1977-11-07 1980-07-16 Wagner Guenter Verfahren zur herstellung von na-alkyl-bzw.na-aryl-sulfonylierten omega-amidinophenyl-alpha-aminoalkylcarbonsaeureamiden
US4879398A (en) * 1987-12-31 1989-11-07 Monsanto Company Process for producing 2,6-disubstituted tyrosine
SE9402880D0 (sv) 1994-08-30 1994-08-30 Astra Ab New peptide derivatives
ID18218A (id) * 1995-01-27 1998-03-19 Novo Nordisk As Senyawa dengan sifat-sifat pelepas hormon pertumbuhan
US5565568A (en) 1995-04-06 1996-10-15 Eli Lilly And Company 2-acylaminopropanamides as tachykinin receptor antagonists
JP3950170B2 (ja) 1995-04-13 2007-07-25 アベンティス・ファーマスーティカルズ・インコーポレイテッド タキキニン受容体アンタゴニスト活性を有する新規な置換されたピペラジン誘導体
WO1997006803A1 (en) 1995-08-21 1997-02-27 Eli Lilly And Company 2-acylaminopropanamides as growth hormone secretagogues
AU7710596A (en) 1995-11-29 1997-06-19 Nihon Nohyaku Co., Ltd. Phenylalanine derivatives, optically active substances, salts or coordination compounds thereof, and their use as fungicides
US5792760A (en) 1997-04-23 1998-08-11 Eli Lilly And Company Bisindoles as tachykinin receptor antagonists
IT1304898B1 (it) 1998-09-08 2001-04-05 Menarini Ricerche Spa Prodotti con caratteristiche basiche aventi attivita' antagonista sulrecettore nk-1 e loro impiego in preparazioni farmaceutiche
EP1055665B1 (en) * 1999-05-28 2003-10-22 Pfizer Products Inc. 3-(3-Hydroxyphenyl)-3-amino-propionamide derivatives
FR2796643B1 (fr) 1999-07-22 2005-04-29 Sod Conseils Rech Applic Derives de 2-arylimino-2, 3-dihydrothiazoles, leurs procedes de preparation et leur utilisation therapeutique
GB0021419D0 (en) 2000-08-31 2000-10-18 Oxford Glycosciences Uk Ltd Compounds
US20020072017A1 (en) * 2000-10-19 2002-06-13 Hudnall Phillip Montgomery Stabilized p-phenylenediamine-type photographic color developers in free base form
DE60128731T2 (de) 2000-10-30 2008-02-07 Janssen Pharmaceutica N.V. Tripeptidylpeptidase-hemmer
EA006507B1 (ru) * 2001-10-15 2005-12-29 Янссен Фармацевтика Н.В. Новые замещенные 4-фенил-4-[1h-имидазол-2-ил] пиперидиновые производные и их применение в качестве селективных непептидных агонистов дельта-опиоидов
US7041681B2 (en) 2002-04-29 2006-05-09 Janssen Pharmaceutica N.V. Compounds as opioid receptor modulators
AU2005224091B2 (en) 2004-03-15 2012-02-02 Janssen Pharmaceutica, N.V. Novel compounds as opioid receptor modulators
JP5070042B2 (ja) * 2004-05-03 2012-11-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 選択的アンドローゲン受容体モジュレーター（ｓａｒｍｓ）としての新規インドール化合物
AU2006223482A1 (en) * 2005-03-14 2006-09-21 Janssen Pharmaceutica, N.V. Process for the preparation of opioid modulators

Also Published As

Publication number Publication date
HUS1700010I1 (hu) 2017-03-28
TW200539876A (en) 2005-12-16
EP2573068A1 (en) 2013-03-27
EP2653465A1 (en) 2013-10-23
AU2005224091A1 (en) 2005-09-29
PL1725537T3 (pl) 2011-12-30
DK2653465T3 (da) 2016-08-22
HK1155726A1 (en) 2012-05-25
BRPI0508820B1 (pt) 2018-04-10
NO20160916A1 (no) 2006-12-14
SI2573068T1 (sl) 2015-03-31
SI2653465T1 (sl) 2016-10-28
EP2653465B1 (en) 2016-07-13
HRP20150305T1 (hr) 2015-04-24
CY2017008I2 (el) 2017-11-14
ES2596434T3 (es) 2017-01-09
IL178040A0 (en) 2006-12-31
LT2653465T (lt) 2016-09-12
HRP20161331T1 (hr) 2016-12-30
US7786158B2 (en) 2010-08-31
SI2298744T1 (sl) 2013-10-30
IL229444A0 (en) 2013-12-31
IL224908A (en) 2015-07-30
US20180325870A1 (en) 2018-11-15
ME01601B (me) 2014-09-20
CY1118096T1 (el) 2017-06-28
ZA200608587B (en) 2008-06-25
LTC1725537I2 (lt) 2018-02-26
HUE029852T2 (en) 2017-04-28
US20140039024A1 (en) 2014-02-06
EP2298744A3 (en) 2011-08-10
HK1105967A1 (en) 2008-02-29
DK2298744T3 (da) 2013-09-02
PL2573068T3 (pl) 2015-06-30
ME02540B (me) 2017-02-20
EP2298744A2 (en) 2011-03-23
NO2017007I2 (no) 2017-02-23
TWI361069B (en) 2012-04-01
US20080096888A1 (en) 2008-04-24
WO2005090315A1 (en) 2005-09-29
BRPI0508820A (pt) 2007-08-07
PL2653465T3 (pl) 2017-01-31
RS51995B (sr) 2012-04-30
US20100324051A1 (en) 2010-12-23
SI1725537T1 (sl) 2011-11-30
EP2298744B1 (en) 2013-06-26
LUC00007I1 (es) 2017-03-03
HK1184432A1 (en) 2014-01-24
DK1725537T3 (da) 2011-10-31
EP3112352A1 (en) 2017-01-04
IL178040A (en) 2013-12-31
CR8655A (es) 2008-09-09
US8609709B2 (en) 2013-12-17
PH12012501640A1 (en) 2015-10-05
PT2298744E (pt) 2013-09-12
PL2298744T3 (pl) 2013-11-29
NL300865I2 (nl) 2020-08-17
NL300865I1 (nl) 2017-03-14
MXPA06010642A (es) 2007-03-26
LUC00007I2 (es) 2017-05-02
CA2560047A1 (en) 2005-09-29
US9205076B2 (en) 2015-12-08
JP2007529527A (ja) 2007-10-25
KR20060131983A (ko) 2006-12-20
US8344011B2 (en) 2013-01-01
BRPI0508820B8 (pt) 2022-11-29
RS54199B1 (sr) 2015-12-31
ES2428008T3 (es) 2013-11-05
US20140256779A1 (en) 2014-09-11
JP4778954B2 (ja) 2011-09-21
IL229444A (en) 2017-03-30
LTPA2017005I1 (lt) 2017-03-27
EP1725537A1 (en) 2006-11-29
MY146972A (en) 2012-10-15
ES2705077T3 (es) 2019-03-21
ATE516274T1 (de) 2011-07-15
NO20064660L (no) 2006-12-14
US7741356B2 (en) 2010-06-22
RS55122B1 (sr) 2016-12-30
CN102786476B (zh) 2017-01-18
NO2017007I1 (no) 2017-02-23
ECSP066856A (es) 2006-11-24
AR095848A2 (es) 2015-11-18
CY1111927T1 (el) 2015-11-04
CN102786476A (zh) 2012-11-21
EP1725537B1 (en) 2011-07-13
US10213415B2 (en) 2019-02-26
ME02221B (me) 2016-02-20
ES2533176T3 (es) 2015-04-08
AU2005224091B2 (en) 2012-02-02
EP2573068B1 (en) 2014-12-31
NO338203B1 (no) 2016-08-08
PT2653465T (pt) 2016-09-22
UA86053C2 (ru) 2009-03-25
PT1725537E (pt) 2011-09-08
DK2573068T3 (en) 2015-02-16
AR048269A1 (es) 2006-04-12
CN1950342B (zh) 2012-09-26
CA2560047C (en) 2013-12-24
KR101166342B1 (ko) 2012-07-18
PT2573068E (pt) 2015-04-27
DK3112352T3 (en) 2019-01-28
NZ549842A (en) 2010-10-29
PH12012501640B1 (en) 2015-10-05
CN1950342A (zh) 2007-04-18
HK1099016A1 (en) 2007-08-03
EP2573068B9 (en) 2015-08-26
US20050203143A1 (en) 2005-09-15
EP3112352B1 (en) 2018-11-21
HRP20130800T1 (en) 2013-09-30
CY2017008I1 (el) 2017-11-14
US20130090478A1 (en) 2013-04-11
US20160030393A1 (en) 2016-02-04
US8772325B2 (en) 2014-07-08
HRP20110694T1 (hr) 2011-12-31
RS52933B (sr) 2014-02-28
US9700542B2 (en) 2017-07-11

Similar Documents

Publication Publication Date Title
ES2367576T3 (es) Nuevos compuestos como moduladores de receptores opioides.
RU2328494C2 (ru) Замещенные пиперазины, (1,4)-диазепины и 2,5-диазабицикло[2.2.1]гептаны в качестве н1-и/или н3-антагонистов гистамина или обратных н3-антагонистов гистамина
AR076381A1 (es) Azetidinil diamidas como inhibidores de monoacilglicerol lipasa
AR047538A1 (es) Piridazinonas como antagonistas de las integrinas alfa4
HRP20100194T8 (hr) Perikondenzirani triciklički spojevi, korisni kao antibakterijska sredstva
AR072900A1 (es) Agentes terapeuticos derivados de pirazolo[3,4-d]pirimidina
MX9603506A (es) Compuestos oxazol aromaticos, heterociclicos y sus usos.
HRP20080477T3 (en) Aryl-pyridine derivatives as 11-beta-hsd1 inhibitors
AR047902A1 (es) Compuestos como inhibidores de ns3 serina proteasa del virus de hepatitis c
HRP20080022T3 (en) Pyrrolopyridine derivatives and their use as crth2 antagonists
JP2015517981A5 (es)
AR036041A1 (es) Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen
JP2002524570A5 (ja) Ｍｄｍ２およびｐ５３間相互作用の阻害剤としてのピペラジン−４−フェニル誘導体
AR062209A1 (es) Pirazolopirimidinas moduladoras de receptores de glutamato metabotropicos mglur5, proceso para su preparacion, medicamentos que las contienen y usos en la prevencion y/o tratamiento de trastornos neurologicos agudos y cronicos.
HRP20110841T1 (hr) Korisni monobaktamski antibiotici
AR062937A1 (es) Compuestos que modulan el receptor cb2
CO5611147A2 (es) Derivados de nicotinamida utiles como inhibidores p38
AR076375A1 (es) Piperazinil azetidinil amidas heteroaromaticas y aromaticas como inhibidores de lipasas de monoacilglicerol.
TW200745029A (en) Sulfonamide derivatives exhibiting PGD2 receptor antagonism
AR079690A1 (es) Derivados heterociclicos de pirrol[2,3-b]piridina, composiciones farmaceuticas que los contienen, procedimiento para prepararlos y uso de los mismos como agentes anticancer.
AR047537A1 (es) Piridazinonaureas como antagonistas de integrinas
RU2002135308A (ru) Производные (тио) мочевины, ингибирующие фактор viiа, их получение и применение
AR049696A1 (es) Derivados de indol
RU2404163C2 (ru) Производные 2,3,4,9-тетрагидро-1h-карбазола в качестве антагонистов рецептора crth2
ME02110B (me) Postupak za pripremu opioidnih modulatora